drugset
drugset / Trial / NCT04361214

Leflunomide in Mild COVID-19 Patients

NCT04361214 ↗

Phase 1 Terminated 11 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

This study aims to examine the tolerability of high dose of leflunomide in patients with COVID-19 who are being managed in the outpatient setting.

Timeline

Start
2020-05-05
Primary completion
2022-01-31
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Leflunomide Small molecule 30 mg —

Indications

COVID-19